Vol 55, No 1 (2021)
Letter to the Editors
Published online: 2020-10-07

open access

Page views 701
Article views/downloads 632
Get Citation

Connect on Social Media

Connect on Social Media

A comment on the paper ‘Biomarkers in Multiple Sclerosis’ by Sapko et al.

Piotr Lewczuk12, Johannes Kornhuber3, Barbara Mroczko2
Pubmed: 33026646
Neurol Neurochir Pol 2021;55(1):115-116.


Not available

Article available in PDF format

View PDF Download PDF file


  1. Andersson M, Alvarez-Cermeño J, Bernardi G, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry. 1994; 57(8): 897–902.
  2. Kulakowska A, Mroczko B, Mantur M, et al. Multiplexing analysis of the polyspecific intrathecal immune response in multiple sclerosis. 2012: Methods.
  3. Reiber H, Lange P. Quantification of virus-specific antibodies in cerebrospinal fluid and serum: sensitive and specific detection of antibody synthesis in brain. Clin Chem. 1991; 37(7): 1153–1160.
  4. Reiber H. Flow rate of cerebrospinal fluid (CSF) — A concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. Journal of the Neurological Sciences. 1994; 122(2): 189–203.
  5. Reiber H, Peter J. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. Journal of the Neurological Sciences. 2001; 184(2): 101–122.
  6. Sapko K, Jamroz-Wiśniewska A, Marciniec M, et al. Biomarkers in Multiple Sclerosis: a review of diagnostic and prognostic factors. Neurol Neurochir Pol. 2020; 54(3): 252–258.
  7. Tumani H, Petereit HF, Gerritzen A, et al. S1 guidelines “lumbar puncture and cerebrospinal fluid analysis” (abridged and translated version). Neurological Research and Practice. 2020; 2(1).